# Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes

Study · id `cardio:ct-nct03004612` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03004612](<https://clinicaltrials.gov/study/NCT03004612>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03004612

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 144 participants.

## Technical summary

Registry record NCT03004612. Randomized; quadruple masking; primary purpose prevention. Start 2016-01 (registry gives no type); primary completion 2019-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 144 participants (enrolled count; ClinicalTrials.gov record NCT03004612, source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)
- Start date: 2016-01 (registry gives no type) (ClinicalTrials.gov record NCT03004612, source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)
- Primary completion: 2019-05 (actual) (ClinicalTrials.gov record NCT03004612, source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)
- Completion: 2019-06 (actual) (ClinicalTrials.gov record NCT03004612, source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)
- Countries: Mexico (ClinicalTrials.gov record NCT03004612, source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03004612-2019-07-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes
- Acronym: PRELLIM
- Condition: Prediabetic State
- Condition: Insulin Resistance
- Intervention (Combination product): Linagliptin + metformin
- Intervention (Drug): Metformin
- Lead sponsor: Universidad de Guanajuato
- Lead sponsor class: OTHER
- Collaborator: Hospital Regional de Alta Especialidad del Bajio
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)

## Provenance

Content hash: b98322622445c87ec0faa524a8403686afd113a95ead1226a4e3d4ea3ae74c2f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
